Treatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency Syndrome
Until recently, long-term regimens consisting of daily intravenous infusions of ganciclovir or foscarnet were the only available treatments for patients with cytomegalovirus (CMV) retinitis, a sight-threatening complication that affects approximately one third of patients in the United States with t...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1997-07, Vol.337 (2), p.105-114 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 114 |
|---|---|
| container_issue | 2 |
| container_start_page | 105 |
| container_title | The New England journal of medicine |
| container_volume | 337 |
| creator | Jacobson, Mark A |
| description | Until recently, long-term regimens consisting of daily intravenous infusions of ganciclovir or foscarnet were the only available treatments for patients with cytomegalovirus (CMV) retinitis, a sight-threatening complication that affects approximately one third of patients in the United States with the acquired immunodeficiency syndrome (AIDS).
1
,
2
In the past three years, the results of 11 randomized clinical trials of four new treatments for AIDS-related CMV retinitis have been reported.
3
–
13
Thus, there are now new therapies from which clinicians can choose.
Incidence and Natural History of CMV Retinitis
CMV end-organ disease has emerged as one of the most common serious complications . . . |
| doi_str_mv | 10.1056/NEJM199707103370207 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79075960</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79075960</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-2403f54cb01878fb34f6476ac5dece81297c064c891001dfeef1e7b3f4d887213</originalsourceid><addsrcrecordid>eNqFkU2LFDEQhoMo67j6C0QIsniR1spHdzrHZVh1Zf1A16tNJl1xM3TSu0lamX9vlhn2IKJ1qUM99RTFS8hTBq8YtN3rj2fvPzCtFSgGQijgoO6RFWuFaKSE7j5ZAfC-kUqLh-RRzluoxaQ-IkeaM9b1bEW-XyY0JWAsdHZ0vStzwB9mmn_6tGT6BYuPvvhMfaSfTfGVy_SXL1e0XCE9tTeLTzjS8xCWOI_ovK2I3dGvuzimqnpMHjgzZXxy6Mfk25uzy_W75uLT2_P16UVjZQel4RKEa6XdAOtV7zZCuk6qzth2RIs941pZ6KTtNasfjA7RMVQb4eTY94ozcUxe7L3Xab5ZMJch-GxxmkzEecmD0qBa3cF_QdZqLbhuK_j8D3A7LynWJwbORQVA3NrEHrJpzjmhG66TDybtBgbDbUbDXzKqW88O6mUTcLzbOYRS5yeHucnWTC6ZaH2-w7iqEuAVe7nHQshDxG3459HfXUmk_Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223953030</pqid></control><display><type>article</type><title>Treatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency Syndrome</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Jacobson, Mark A</creator><contributor>Wood, Alastair J.J.</contributor><creatorcontrib>Jacobson, Mark A ; Wood, Alastair J.J.</creatorcontrib><description>Until recently, long-term regimens consisting of daily intravenous infusions of ganciclovir or foscarnet were the only available treatments for patients with cytomegalovirus (CMV) retinitis, a sight-threatening complication that affects approximately one third of patients in the United States with the acquired immunodeficiency syndrome (AIDS).
1
,
2
In the past three years, the results of 11 randomized clinical trials of four new treatments for AIDS-related CMV retinitis have been reported.
3
–
13
Thus, there are now new therapies from which clinicians can choose.
Incidence and Natural History of CMV Retinitis
CMV end-organ disease has emerged as one of the most common serious complications . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199707103370207</identifier><identifier>PMID: 9211681</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Administration, Oral ; AIDS-Related Opportunistic Infections - drug therapy ; AIDS/HIV ; Antiviral Agents - pharmacokinetics ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; Blindness ; Cytomegalovirus ; Cytomegalovirus Retinitis - drug therapy ; Cytosine - analogs & derivatives ; Cytosine - pharmacokinetics ; Cytosine - therapeutic use ; Deoxyribonucleic acid ; DNA ; Drug Implants ; Drug Therapy, Combination ; Foscarnet - pharmacokinetics ; Foscarnet - therapeutic use ; Ganciclovir - pharmacokinetics ; Ganciclovir - therapeutic use ; HIV ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Infectious diseases ; Kinases ; Medical sciences ; Mutation ; Organophosphonates ; Organophosphorus Compounds - pharmacokinetics ; Organophosphorus Compounds - therapeutic use ; Viral diseases ; Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</subject><ispartof>The New England journal of medicine, 1997-07, Vol.337 (2), p.105-114</ispartof><rights>Copyright © 1997 Massachusetts Medical Society. All rights reserved.</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c460t-2403f54cb01878fb34f6476ac5dece81297c064c891001dfeef1e7b3f4d887213</citedby><cites>FETCH-LOGICAL-c460t-2403f54cb01878fb34f6476ac5dece81297c064c891001dfeef1e7b3f4d887213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199707103370207$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJM199707103370207$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2720702$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9211681$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Wood, Alastair J.J.</contributor><creatorcontrib>Jacobson, Mark A</creatorcontrib><title>Treatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency Syndrome</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Until recently, long-term regimens consisting of daily intravenous infusions of ganciclovir or foscarnet were the only available treatments for patients with cytomegalovirus (CMV) retinitis, a sight-threatening complication that affects approximately one third of patients in the United States with the acquired immunodeficiency syndrome (AIDS).
1
,
2
In the past three years, the results of 11 randomized clinical trials of four new treatments for AIDS-related CMV retinitis have been reported.
3
–
13
Thus, there are now new therapies from which clinicians can choose.
Incidence and Natural History of CMV Retinitis
CMV end-organ disease has emerged as one of the most common serious complications . . .</description><subject>Administration, Oral</subject><subject>AIDS-Related Opportunistic Infections - drug therapy</subject><subject>AIDS/HIV</subject><subject>Antiviral Agents - pharmacokinetics</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blindness</subject><subject>Cytomegalovirus</subject><subject>Cytomegalovirus Retinitis - drug therapy</subject><subject>Cytosine - analogs & derivatives</subject><subject>Cytosine - pharmacokinetics</subject><subject>Cytosine - therapeutic use</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Drug Implants</subject><subject>Drug Therapy, Combination</subject><subject>Foscarnet - pharmacokinetics</subject><subject>Foscarnet - therapeutic use</subject><subject>Ganciclovir - pharmacokinetics</subject><subject>Ganciclovir - therapeutic use</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Kinases</subject><subject>Medical sciences</subject><subject>Mutation</subject><subject>Organophosphonates</subject><subject>Organophosphorus Compounds - pharmacokinetics</subject><subject>Organophosphorus Compounds - therapeutic use</subject><subject>Viral diseases</subject><subject>Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU2LFDEQhoMo67j6C0QIsniR1spHdzrHZVh1Zf1A16tNJl1xM3TSu0lamX9vlhn2IKJ1qUM99RTFS8hTBq8YtN3rj2fvPzCtFSgGQijgoO6RFWuFaKSE7j5ZAfC-kUqLh-RRzluoxaQ-IkeaM9b1bEW-XyY0JWAsdHZ0vStzwB9mmn_6tGT6BYuPvvhMfaSfTfGVy_SXL1e0XCE9tTeLTzjS8xCWOI_ovK2I3dGvuzimqnpMHjgzZXxy6Mfk25uzy_W75uLT2_P16UVjZQel4RKEa6XdAOtV7zZCuk6qzth2RIs941pZ6KTtNasfjA7RMVQb4eTY94ozcUxe7L3Xab5ZMJch-GxxmkzEecmD0qBa3cF_QdZqLbhuK_j8D3A7LynWJwbORQVA3NrEHrJpzjmhG66TDybtBgbDbUbDXzKqW88O6mUTcLzbOYRS5yeHucnWTC6ZaH2-w7iqEuAVe7nHQshDxG3459HfXUmk_Q</recordid><startdate>19970710</startdate><enddate>19970710</enddate><creator>Jacobson, Mark A</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19970710</creationdate><title>Treatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency Syndrome</title><author>Jacobson, Mark A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-2403f54cb01878fb34f6476ac5dece81297c064c891001dfeef1e7b3f4d887213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Administration, Oral</topic><topic>AIDS-Related Opportunistic Infections - drug therapy</topic><topic>AIDS/HIV</topic><topic>Antiviral Agents - pharmacokinetics</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blindness</topic><topic>Cytomegalovirus</topic><topic>Cytomegalovirus Retinitis - drug therapy</topic><topic>Cytosine - analogs & derivatives</topic><topic>Cytosine - pharmacokinetics</topic><topic>Cytosine - therapeutic use</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Drug Implants</topic><topic>Drug Therapy, Combination</topic><topic>Foscarnet - pharmacokinetics</topic><topic>Foscarnet - therapeutic use</topic><topic>Ganciclovir - pharmacokinetics</topic><topic>Ganciclovir - therapeutic use</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Kinases</topic><topic>Medical sciences</topic><topic>Mutation</topic><topic>Organophosphonates</topic><topic>Organophosphorus Compounds - pharmacokinetics</topic><topic>Organophosphorus Compounds - therapeutic use</topic><topic>Viral diseases</topic><topic>Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jacobson, Mark A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jacobson, Mark A</au><au>Wood, Alastair J.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency Syndrome</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1997-07-10</date><risdate>1997</risdate><volume>337</volume><issue>2</issue><spage>105</spage><epage>114</epage><pages>105-114</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Until recently, long-term regimens consisting of daily intravenous infusions of ganciclovir or foscarnet were the only available treatments for patients with cytomegalovirus (CMV) retinitis, a sight-threatening complication that affects approximately one third of patients in the United States with the acquired immunodeficiency syndrome (AIDS).
1
,
2
In the past three years, the results of 11 randomized clinical trials of four new treatments for AIDS-related CMV retinitis have been reported.
3
–
13
Thus, there are now new therapies from which clinicians can choose.
Incidence and Natural History of CMV Retinitis
CMV end-organ disease has emerged as one of the most common serious complications . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>9211681</pmid><doi>10.1056/NEJM199707103370207</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1997-07, Vol.337 (2), p.105-114 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79075960 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Administration, Oral AIDS-Related Opportunistic Infections - drug therapy AIDS/HIV Antiviral Agents - pharmacokinetics Antiviral Agents - therapeutic use Biological and medical sciences Blindness Cytomegalovirus Cytomegalovirus Retinitis - drug therapy Cytosine - analogs & derivatives Cytosine - pharmacokinetics Cytosine - therapeutic use Deoxyribonucleic acid DNA Drug Implants Drug Therapy, Combination Foscarnet - pharmacokinetics Foscarnet - therapeutic use Ganciclovir - pharmacokinetics Ganciclovir - therapeutic use HIV Human immunodeficiency virus Human viral diseases Humans Infectious diseases Kinases Medical sciences Mutation Organophosphonates Organophosphorus Compounds - pharmacokinetics Organophosphorus Compounds - therapeutic use Viral diseases Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye |
| title | Treatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency Syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T14%3A57%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Cytomegalovirus%20Retinitis%20in%20Patients%20with%20the%20Acquired%20Immunodeficiency%20Syndrome&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Jacobson,%20Mark%20A&rft.date=1997-07-10&rft.volume=337&rft.issue=2&rft.spage=105&rft.epage=114&rft.pages=105-114&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM199707103370207&rft_dat=%3Cproquest_cross%3E79075960%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223953030&rft_id=info:pmid/9211681&rfr_iscdi=true |